Mallinckrodt Plc has received various subpoenas and other information requests related to the distribution, marketing and sale of its opioid products.
The U.K.-based pharmaceutical company has been named in several lawsuits related to the alleged fueling of the opioid endemic in the U.S. On Dec. 20, 2017, New Mexico Attorney General Hector Balderas added claims against Mallinckrodt in a lawsuit seeking economic damages from opioid manufacturers and wholesale distributors.
Mallinckrodt received a subpoena from the Department of Justice in July 2017, a civil investigative demand from the Missouri Attorney General in August 2017 and a subpoena from the New Hampshire Attorney General in September 2017, according to a Form 10-K filing.
In January, the company received a subpoena and civil investigative demand from the Kentucky Attorney General and a civil investigative demand from the Washington Attorney General. It also received a subpoena from the Alaska Attorney General in February.
On Jan. 27, the company got a grand jury subpoena from the U.S. Attorneys' Office for the Southern District of Florida related to its distribution, marketing and sale practices relating to its oxymorphone generic products.
Mallinckrodt said it is in the process of responding to the subpoenas and civil investigative demands. It added that it intends to cooperate fully in investigations by the coalition of State Attorneys General into the role manufacturers and distributors may have had in contributing to the increased use of opioids in the U.S.
